Patent intelligence · US
US 2019153441
MATERIALS AND METHODS FOR TREATMENT OF AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA
MATERIALS AND METHODS FOR TREATMENT OF AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA
Patent details — US 2019153441
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 23, 2019
- Expiration
- May 18, 2039
- Applicant
- CASEBIA THERAPEUTICS LLP [GB]
- CPC classes
- A61K 31/ 7088 A I, A61K 38/ 46 A I, A61K/317088, A61K/38465
Quick answer
US 2019153441 (MATERIALS AND METHODS FOR TREATMENT OF AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA) is held by CASEBIA THERAPEUTICS LLP [GB]. Status: granted. Granted May 23, 2019. Expires May 18, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CASEBIA THERAPEUTICS LLP [GB]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 31/ 7088 A I, A61K 38/ 46 A I, A61K/317088, A61K/38465, A61P 27/ 02 A I, A61P/2702
More from CASEBIA THERAPEUTICS LLP [GB]
Related pharmaceutical patents in our USPTO index.
-
WO 2024052517
USAGE MÉDICAL D'ANTICORPS ANTI-CCR8 ET PROGRAMME DE DOSAGE
granted -
CN 117186084
Pranlerivir sulfonate, and pharmaceutical preparation, preparation method and application thereof in treatment of herpes virus
granted -
CN 115348859
Ophthalmic formulations comprising n-[5-(aminosulfonyl)-4-methyl-1, 3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl) phenyl] acetamide hemihydrate
granted -
CN 115003329
Parapoxvirus for conditioning and treating coronavirus infections
granted -
BR 112021015776
Edição de gene para hemofilia a com expressão de fator viii melhorada
granted -
WO 2021152186
ANTICORPS CCR8 POUR APPLICATIONS THÉRAPEUTIQUES
granted -
DE 102019218587
Kontrastmittelbasierte Gefäßdarstellung
granted -
DE 102019218589
Simultane Bilddarstellung von zwei unterschiedlichen funktionellen Bereichen
granted
Frequently asked questions
What is US patent 2019153441?
US 2019153441 (MATERIALS AND METHODS FOR TREATMENT OF AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA) is held by CASEBIA THERAPEUTICS LLP [GB]. Status: granted. Granted May 23, 2019. Expires May 18, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2019153441?
CASEBIA THERAPEUTICS LLP [GB] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 24 pharmaceutical patents for this assignee.
When does US 2019153441 expire?
Our index shows an expiration date of May 18, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.